inhibitor, or angiotensin receptor blocker therapy. Results. A significant reduction in HbA 1c from the index measure to the postperiod measure was observed (p < 0.001). No significant change was noted in weight or number of patients at goal blood pressure among the preperiod, index, and postperiod measures. No change was observed in the secondary outcomes during the study time intervals. Conclusion. Integrating a pharmacist into a private physician practice significantly improved patient glycemic control and maintained patients' weight and the number of patients at blood pressure goal. Clinic adherence with the American Diabetes Association recommendations was sustained.
T
oday's primary care providers are increasingly inundated with administrative and clinical responsibilities that place great demand on their schedules, leaving them less time to devote to direct patient care. A study of young physicians practicing in California found that the percentage of physicians who felt that they were able to spend sufficient time with their patients fell from 80% in 1991 to 56% in 1996. 1 Advances in medical care, changing disease patterns, greater demand for clinical accountability, and evolving professional norms, among other factors, have created heightened expectations for performance in primary care practice. 2 With the 25% increase in medication use over the past decade, primary care providers are spending more time perusing the growing body of literature on medication efficacy and maintaining pa-Am J Health-Syst Pharm-Vol 65 Jan 15, 2008 tients' medication profiles. 3 In a typical 18-minute office visit, primary care providers are expected to relieve symptoms, cure disease, diagnose potentially serious conditions, and provide chronic illness management and preventive care. 4, 5 The American Diabetes Association (ADA) 6 and the American Association of Clinical Endocrinologists 7 have published evidence-based recommendations on the standard of care for patients with diabetes mellitus. A study using the National Health and Nutrition Examination Survey's 1999-2000 data found deficiencies in diabetes care. 8 Of the patients included in the study, 37% achieved a glycosylated hemoglobin (HbA 1c ) concentration of <7%, 36% had a blood pressure of <130/80 mm Hg, 48% had a total cholesterol level of <200 mg/dL, and only 7.3% achieved all three treatment goals. The benefits of maintaining optimal glycemic, blood pressure, and lipidemic control are well documented. 6 Providing diabetes self-management education and preventive care and reinforcing lifestyle modifications help patients optimize metabolic control, prevent and manage complications, and maximize their quality of life.
The 2003 Institute of Medicine (IOM) report on racial and ethnic health disparities stated that African Americans and Hispanics with diabetes receive lower quality of health care than do other ethnicities. 9 As type 2 diabetes mellitus predominates in these ethnic groups, innovative public health initiatives have been instituted to eliminate such health disparities. Studies demonstrating the effectiveness of collaborative pharmacist-physician diabetes models have been conducted primarily in patient populations with few minorities and rarely in the privatepractice setting.
As the medical community looks for ways to improve the delivery of long-term care, pharmacists are collaborating successfully with other health care practitioners to improve the outcomes of patients with diabetes. [10] [11] [12] [13] [14] Studies conducted in community pharmacies, managed care settings, and Veterans Affairs (VA) medical centers have found reduced HbA 1c values overall and an increase in the number of pharmacist-assisted patients suffering from diabetes with an optimal HbA 1c . Pharmacists can augment diabetes care by providing medication management from drug therapy initiation to, if necessary, medication modification or education. The manner in which this collaboration is structured depends significantly on the state laws and regulations under which the pharmacist practices.
Before this study, clinical outcomes associated with this pharmacy collaborative model had rarely been evaluated in a private physician practice serving a predominately African-American population. The purpose of this study was to evaluate whether pharmacists working in collaboration with primary care providers in an urban, private physician practice could help improve clinical outcomes in patients with type 1 or 2 diabetes.
Methods
A retrospective, time-series, single-group design was chosen for this study. All patients over 18 years of age who had a documented diagnosis of type 1 or 2 diabetes mellitus for at least six months and were referred to the pharmacy clinic for medication management between March 1, 2002, and August 31, 2003, were eligible for study inclusion. Patients receiving oral or insulin therapy (or both) for diabetes were included in this study. Women who were pregnant or became pregnant during the study period were excluded. Institutional review board approval was obtained through the Johns Hopkins Hospital before study initiation.
Clinic format and intervention. New patients were scheduled for 45-minute time slots with the pharmacist; follow-up visits lasted 30 minutes. Follow-up visits were scheduled with the pharmacist as needed for medication management; patients generally alternated between the pharmacist and the primary care provider depending on patient needs.
The pharmacy clinic, located within the physician's practice, allowed pharmacists and other primary care providers to interact daily. The clinic scheduled patient visits on Tuesdays and Thursdays, half day each, and Wednesdays for a full day. The daily number of patient visits scheduled ranged from five to seven, depending on the number of new patient visits. Clinic hours were occasionally extended for walk-ins or same-day consultations with primary care providers.
The pharmacy clinic was managed by two pharmacists, both of whom had a doctor of pharmacy degree and two years of pharmacy residency training. One was a board-certified pharmacotherapy specialist. They each evaluated patients, oversaw the operation of the pharmacy clinic, and provided a clinical training site for regional schools of pharmacy. All of the primary care pharmacists working with the Johns Hopkins Community Physicians operated under a leased-employee agreement with a renewable two-year lease.
The practice focused on internal medicine issues, with the majority of patients having multiple risk factors for cardiovascular disease. Services provided in the pharmacy clinic-part of a course of treatment established by the primary care provider-included evidence-based medication management and adherence counseling, lifestyle modification, device and disease-state education, and helping patients enroll in medication assistance programs.
All patients with diabetes referred to the pharmacy clinic had their vital signs checked and medication regimens evaluated by the pharmacist.
Am J Health-Syst Pharm-Vol 65 Jan 15, 2008 Patients typically returned every two to six weeks as determined by the severity of their illness or level of educational need. Once the initial goals were met, a patient would be discharged from the clinic or asked to return in three to six months for a follow-up appointment. When recommending a medication change, the pharmacist discussed the patient's needs with his or her primary care provider or designee. Almost all of the pharmacist's recommendations were accepted. If the patient was experiencing an acute clinical problem (e.g., unstable angina, symptomatic hyperglycemia or hypoglycemia, hypertensive urgency), he or she was triaged according to protocol. After the patient's appointment, the pharmacist wrote a progress note and billed for services according to "incident to" regulations. The note was then reviewed and signed by the primary care provider. If a patient with an acute symptom or change in health status was seen by the physician or designee, the physician evaluated the patient, documented the visit, and billed for services. In this instance, a separate bill for pharmacy services was not prepared.
Outcomes. The primary objective of this study was to evaluate whether a pharmacist working in collaboration with other health care providers could improve HbA 1c levels, help patients maintain a healthy weight, and increase the number of patients with a target blood pressure of <130/80 mm Hg. The secondary objectives were to evaluate compliance with select ADA guidelines, such as smoking cessation, initiation of aspirin therapy, and initiation of angiotensinconverting-enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy.
Data were collected for the six months before (preperiod measure), the day of (index measure), and six months after (postperiod measure) the first visit with the pharmacist. HbA 1c levels were checked less frequently than were other values. An algorithm was developed to provide a clinical basis by which the preperiod, index, and postperiod data were collected and evaluated. The exact date of the first and third data collection periods were calculated based on the index date. The HbA 1c was the first outcome collected for each patient. Per study protocol, the HbA 1c value closest to the preperiod, index, and postperiod measurement dates were recorded. At that point, data for the other endpoints (e.g., blood pressure, weight, secondary measures) were collected from the progress note dated closest to the HbA 1c measurement. To minimize investigator bias and inconsistencies in data collection, a pharmacist not involved in patient care at the clinic was responsible for chart review.
Statistical analyses. The change in HbA 1c values from before the point of referral to the patient's pharmacybased clinic entry (i.e., preperiod measure to index measure) and the change in values from clinic entry to the end of study period (i.e., index measure to postperiod measure) were compared using a multiple regression approach and generalized estimating equations with robust variance estimation. 15 Potential covariates evaluated for inclusion in the final multivariate model were age, race, sex, body mass index, height, and weight. All secondary outcomes were assessed using chi-square analysis or Fisher's exact test, as appropriate. The a priori level of significance was 0.05. Statistical analyses were performed using Stata software, version 9.0 (Stata Corporation, College Station, TX).
Results
Baseline characteristics. Of the 222 patients seen during the study period, 77 met inclusion criteria. Most (103) of the patients who did not meet study criteria either did not have diabetes, were newly diagnosed with diabetes, or had gestational diabetes. Of the remaining 42 patients excluded, 2 transferred to another clinic before seeing the pharmacist, 14 were never seen by the pharmacist, and 26 were missing one of the study's three measurements. Baseline demographics are outlined in Table  1 . Sixty-four patients (83%) were African American.
Changes in primary and secondary outcomes. Values for the primary and secondary outcomes for each study period are presented in Table  2 . The HbA 1c value was not significantly reduced from the preperiod measure to the index measure (mean change, -0.1%) (p = 0.79; 95% confidence interval [CI], -0.3% to 0.2%). However, there was a significant reduction in HbA 1c from the index measure to the postperiod measure (mean change, -0.9%) (p < 0.0001; 95% CI, -1.2% to -0.4%). The difference among these changes over study periods was significant (p < 0.0001). No significant change was noted in weight or number of patients at goal blood pressure among the three time periods studied. No difference was detected in the secondary study measures (the number of patients treated with an ACE inhibitor, ARB, or aspirin and who smoked) among the study periods.
Discussion
In a primary health care system with overextended practitioners, diminishing resources, and a rising prevalence of chronic disease, it is essential for health care practitioners to find innovative ways to ameliorate the current primary care model. According to a 2001 IOM report, health care systems are required to continuously monitor the results of the care they provide and use that information for quality improvement and assurance. 16 The purpose of this study was to provide data on the clinical outcomes of a multidisciplinary model incorporating a clinical pharmacist into the medical care model of a private-practice physician serving primarily African Americans. This study found a significant change of HbA 1c values-by -0.9%-after the first pharmacist visit. The clinical pharmacists were able to optimize standard medical care by providing medication dosage adjustments as needed and patient education. Continual patient reinforcement that focused on healthy lifestyles and medication issues may have led to improved medication adherence, which would be reflected in improved glycemic control.
Given the preliminary nature of this study, it was conducted using a time-series (pre-post) study design. In future studies, a prospective, cohort study design should be used to improve the ability to draw causal inferences from the study results. The study was conducted retrospectively and involved the review of patients' charts. Inconsistencies, typical with retrospective chart reviews, were noted in the documentation of patient information as was the frequency with which laboratory test values were measured. As a result, it became necessary to exclude patients whose data, based on a clinically based algorithm, could not be exclusively categorized as occurring in the preperiod measure, index measure, or postperiod measure (collaborative model) time period. In addition, referral bias may have affected the results, since physicians chose to refer patients based upon clinical judgment. This factor would limit the generalizability of these findings.
A number of factors might explain the lack of significant improvement in blood pressure, weight, and secondary outcomes. Blood pressure data could have been affected by measurement bias, as multiple health care practitioners take patients' blood pressures in the clinic. In an attempt to control for this variation, blood pressure was not analyzed as a continuous variable but rather as nominal data (i.e., at goal or not). The apparent negligible change in the weight category may be because weight gain tends to be associated with intensive glucose control. Although patients are encouraged about and advised on weight loss in pharmacy clinic visits, it is common practice to initiate insulin, sulfon ylurea, or a thiazolidinedioneagents that typically result in weight Table 1 .
Patient Demographics at Clinic Entry (n = 77)

Variable Value
Mean ± S.D. age (yr) 64 ± 10. gain. 17 It is possible that the pharmacists' frequent positive reinforcement on weight loss during diabetic therapy enabled the patients to maintain their weight instead of realizing the usual weight gain associated with such therapy.
In terms of the secondary outcomes, a large percentage (88%) of patients were not smoking tobacco at baseline, which may account for the negligible improvement seen in this measure. A similar argument could be made for the ACE inhibitor and ARB therapy measures as well; 81% of patients were taking an ACE inhibitor or an ARB at baseline, and those who were not may have had conditions (e.g., cough, bilateral renal artery stenosis, hyperkalemia, angioedema) to preclude use. In the case of aspirin, only 60% of patients were receiving such therapy at baseline, and no improvement was noted over the study period. This may be indicative of a need for further intervention and better documentation of aspirin use by all health care practitioners to ensure adherence to those recommendations.
Similar multidisciplinary models of pharmacists working in community pharmacies, VA medical centers, and managed care settings have been previously described in the literature. Cranor and Christensen 10 assessed the outcomes of community-based pharmaceutical care services using a cohort of patients from the Asheville Project, an innovative program offering disease-state management services in collaboration with physicians in North Carolina. This study found a significant reduction in mean ± S.D. HbA 1c , from 7.5% ± 1.5% at baseline to 7.0% ± 1.3% over 7-9 months (p < 0.01). A significant increase in the percentage of patients with optimal HbA 1c values (p = 0.04) was demonstrated as well. 10 These results are corroborated by another study conducted in a VA setting, in which pharmacists were shown to demonstrate a significant improvement in mean ± S.D. HbA 1c , from 10.3% ± 2.2% to 6.9% ± 1.1% over 9-12 months (p < 0.001).
11 A recently published study showed a 1.6% reduction in HbA 1c (p < 0.001) and demonstrated an improvement in the frequency of the clinic's adherence to ADA's preventive care recommendations.
14 These clinic-based models provided services similar to those offered in the pharmacy clinic described in this article.
Multiple explanations have been proposed for the existence of health care disparities, including patient mistrust and refusal to follow recommendations. 9 Anecdotally, the patients in this study expressed satisfaction with the services they received and time spent in the pharmacy clinic, which was likely due to their perceptions of the provider's attentiveness to their medical concerns. The majority of patients served in this pharmacy clinic are African American. Given the paucity of literature evaluating pharmacy clinic effectiveness in controlling diabetes mellitus in African Americans, this study can serve as a pilot for future research in this patient population.
The fundamental goal of the pharmacy medication management clinic is to improve patient health outcomes. This study described a successful partnership between pharmacists and other health care practitioners to provide comprehensive, multidisciplinary chronic care. With the ever-increasing pressure on primary care providers, the health care community will need to continue to evaluate innovative practice models that provide quality care to patients.
Conclusion
Integrating a pharmacist into a private physician practice significantly improved patient glycemic control and maintained patients' weight and the number of patients at blood pressure goal. Clinic adherence with ADA recommendations was sustained.
